Advertisement
A vs DHR
Which Stock Would AI Choose? Agilent Technologies (A) vs. Danaher (DHR) Stock Comparison
Key Takeaways
- Agilent Technologies reported stronger year-over-year revenue growth in its most recent quarter compared with Danaher, with both companies operating in the life sciences tools and services sector.
- Agilent raised its full-year fiscal 2026 guidance following a beat on earnings and revenue, while Danaher adjusted its outlook amid acquisition integration and variable end-market demand.
- Both stocks have delivered dividends recently, with Agilent declaring $0.255 per share and Danaher $0.40 per share, providing income alongside capital appreciation potential.
- Agilent’s stock has shown resilience near 52-week highs amid product launches and operational improvements, whereas Danaher has focused on leadership transition and large-scale acquisitions.
- Sector exposure overlaps in life sciences and diagnostics, but Agilent emphasizes analytical instruments and applied markets while Danaher spans broader biotechnology and diagnostics platforms.
- Recent market activity highlights Agilent’s margin expansion and Danaher’s scale advantages, creating distinct risk-return profiles for investors seeking exposure to healthcare innovation.
Introduction
Agilent Technologies (A) and Danaher (DHR) represent two prominent players in the life sciences tools and services industry, making them natural subjects for comparison among investors evaluating healthcare sector exposure. Both companies supply instruments, consumables, and services critical to pharmaceutical research, diagnostics, and applied sciences, yet they differ in scale, end-market focus, and recent operational execution. Portfolio managers and active traders often examine such pairs to assess relative performance, valuation differentials, and momentum shifts within a defensive yet innovation-driven segment. This analysis draws on verifiable financial metrics and developments from recent weeks to highlight contrasts in business models and market positioning without forecasting future outcomes.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies designs and manufactures analytical instruments, software, and consumables for life sciences, diagnostics, and applied chemical markets. In its third quarter of fiscal 2026, the company reported revenue of $1.88 billion, reflecting 8.1% reported growth and 7.3% core growth year over year, alongside a non-GAAP earnings per share of $1.56 that exceeded guidance. Management raised full-year fiscal 2026 revenue guidance to a range of $7.49 billion to $7.51 billion, implying 5.8% to 6% core growth, and non-GAAP EPS guidance to $6.18–$6.21. Recent market activity has been supported by the launch of the FDA-cleared S540MD Slide Scanner System and continued improvement in China demand. The stock has traded near the upper end of its 52-week range, with analysts maintaining a moderate buy consensus and an average price target above current levels. Operational execution through the Ignite Operating System has contributed to margin expansion and pricing discipline.
Danaher (DHR) Overview and Recent Performance
Danaher Corporation operates across biotechnology, life sciences, and diagnostics segments, offering a diversified portfolio that includes bioprocessing, lab automation, and medical technologies. In the second quarter of 2026, the company posted revenue of $6.3 billion, up 5.5% year over year with 3% core growth, and non-GAAP adjusted diluted EPS of $1.94, an 8% increase. Full-year guidance was updated following the earlier-than-expected close of the Masimo acquisition. Recent market activity includes a leadership transition with the appointment of Julie Sawyer Montgomery as president and chief executive officer in August 2026, alongside the declaration of a quarterly dividend of $0.40 per share. The stock has experienced moderate price fluctuations amid integration efforts and variable academic and bioprocessing demand, while maintaining a focus on the Danaher Business System for cost productivity. Analysts maintain a buy consensus with price targets reflecting potential upside from scale and recurring revenue streams.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots optimized for prevailing market conditions. Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers, yet only the strongest performers with suitable strategies earn placement in this section. Available bots display varied statistics, including win rates often ranging from 55% to 75%, profit factors between 1.2 and 2.5, and maximum drawdowns typically under 20% depending on the strategy and timeframe. Each bot employs distinct trading styles, timeframes, performance histories, and ticker sets, allowing users to match algorithms to specific risk tolerances and market views. Review the live data and backtested metrics on the platform to identify bots aligned with individual objectives.
Head-to-Head Comparison
Agilent Technologies operates with a more focused portfolio centered on analytical chemistry and diagnostics instrumentation, delivering higher recent core revenue growth rates than Danaher’s broader platform that includes significant biotechnology and environmental solutions exposure. Danaher’s larger market capitalization provides greater scale and diversification but has coincided with lower core growth in recent quarters amid acquisition-related noise and end-market variability. Both companies benefit from recurring revenue from consumables and services, though Agilent has demonstrated more pronounced margin expansion in its latest reporting period. Risk factors differ: Agilent faces potential supply-chain and tariff pressures, while Danaher contends with integration risks from recent deals and leadership changes. Market sentiment has favored Agilent’s consistent beats and guidance raises, whereas Danaher’s positioning emphasizes long-term platform stability and cash-flow generation. Relative performance in recent weeks reflects these contrasts, with Agilent showing tighter correlation to life-sciences demand recovery.
Tickeron AI Verdict
Based on observable factors such as recent trend consistency, earnings beats, margin trends, and relative positioning within the sector, Tickeron’s AI models would currently assign a higher probabilistic preference to Agilent Technologies (A) over Danaher (DHR). Agilent’s stronger year-over-year core growth, raised guidance, and product-driven catalysts align with more stable momentum signals in the evaluated period, while Danaher’s profile reflects scale advantages tempered by integration variables and moderated core expansion. This assessment remains probabilistic and subject to evolving market data rather than a definitive recommendation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and DHR is a Buy.
A | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 46 | 77 | |
PRICE GROWTH RATING 1..100 | 22 | 53 | |
P/E GROWTH RATING 1..100 | 28 | 42 | |
SEASONALITY SCORE 1..100 | 65 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (8) in the Medical Specialties industry is in the same range as A (11) in the Biotechnology industry. This means that DHR’s stock grew similarly to A’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as A (100) in the Biotechnology industry. This means that DHR’s stock grew similarly to A’s over the last 12 months.
A's SMR Rating (46) in the Biotechnology industry is in the same range as DHR (77) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's Price Growth Rating (22) in the Biotechnology industry is in the same range as DHR (53) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's P/E Growth Rating (28) in the Biotechnology industry is in the same range as DHR (42) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
| A | DHR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 71% | 2 days ago 67% |
| Stochastic ODDS (%) | 2 days ago 58% | 2 days ago 60% |
| Momentum ODDS (%) | 2 days ago 66% | 2 days ago 55% |
| MACD ODDS (%) | 2 days ago 61% | 2 days ago 60% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 63% |
| TrendMonth ODDS (%) | 2 days ago 61% | 2 days ago 65% |
| Advances ODDS (%) | 11 days ago 62% | 5 days ago 54% |
| Declines ODDS (%) | 2 days ago 63% | 2 days ago 60% |
| BollingerBands ODDS (%) | 2 days ago 70% | 2 days ago 57% |
| Aroon ODDS (%) | 2 days ago 67% | 2 days ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 3 FA rating(s) are green while DHR’s FA Score has 1 green FA rating(s).
- A’s FA Score: 3 green, 2 red.
- DHR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 4 TA indicator(s) are bullish while DHR’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 4 bullish, 4 bearish.
- DHR’s TA Score: 4 bullish, 6 bearish.
Price Growth
A (@Medical Specialties) experienced а -3.56% price change this week, while DHR (@Medical Specialties) price change was -5.20% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.80%. For the same industry, the average monthly price growth was +3.90%, and the average quarterly price growth was +46.85%.
Reported Earning Dates
A is expected to report earnings on Nov 30, 2026.
DHR is expected to report earnings on Oct 21, 2026.
Industries' Descriptions
@Medical Specialties (-2.80% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | -4.42% | ||
| TMO - DHR | 73% Closely correlated | -3.34% | ||
| RGEN - DHR | 68% Closely correlated | -7.80% | ||
| BIO - DHR | 64% Loosely correlated | -5.86% | ||
| A - DHR | 60% Loosely correlated | -3.27% | ||
| BRKR - DHR | 58% Loosely correlated | -4.34% | ||
More | ||||